Phospho-ERKTHR202/Tyr214 Is Overexpressed in Hairy Cell Leukemia and Is a Useful Diagnostic Marker in Bone Marrow Trephine Sections

2013 ◽  
Vol 37 (2) ◽  
pp. 305-308 ◽  
Author(s):  
Douglas W. Warden ◽  
Sarah Ondrejka ◽  
Jeffrey Lin ◽  
Lisa Durkin ◽  
Juraj Bodo ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Hairy Cell Leukemia ◽  
Diagnostic Marker ◽  
Hairy Cell ◽  
Cell Leukemia ◽  
Bone Marrow Trephine

A Comprehensive Immunophenotypic Marker Analysis of Hairy Cell Leukemia in Paraffin-Embedded Bone Marrow Trephine Biopsies–A Tissue Microarray Study

2014 ◽  
Vol 21 (1) ◽  
pp. 203-211 ◽  
Author(s):  
Judit Tóth-Lipták ◽  
Klára Piukovics ◽  
Zita Borbényi ◽  
Judit Demeter ◽  
Enikő Bagdi ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Tissue Microarray ◽  
Hairy Cell Leukemia ◽  
Hairy Cell ◽  
Cell Leukemia ◽  
Bone Marrow Trephine ◽  
Microarray Study ◽  
Marker Analysis

Efficacy of Annexin A1 Immunostaining in Bone Marrow for the Diagnosis of Hairy Cell Leukemia

2019 ◽  
Vol 9 (4) ◽  
pp. 236
Author(s):  
Chang-Hun Park ◽  
Hyun-Young Kim ◽  
Sang-Yong Shin ◽  
Hee-Jin Kim ◽  
Chul Won Jung ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Hairy Cell Leukemia ◽  
Annexin A1 ◽  
Hairy Cell ◽  
Cell Leukemia

scholarly journals Treatment of hairy cell leukemia with recombinant alpha 2 interferon

Blood ◽  
1985 ◽  
Vol 65 (3) ◽  
pp. 644-648 ◽  
Author(s):  
MJ Ratain ◽  
HM Golomb ◽  
JW Vardiman ◽  
EE Vokes ◽  
RH Jacobs ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Intracerebral Hemorrhage ◽  
Hairy Cell Leukemia ◽  
Hairy Cell ◽  
Cell Leukemia ◽  
Bone Marrow Biopsies ◽  
Subcutaneous Injections

Abstract Nine patients with progressive hairy cell leukemia were treated with subcutaneous injections of recombinant alpha 2 interferon (2 to 10 X 10(6) U/m2) three times weekly. Eight patients completed at least eight weeks of treatment and were evaluable; one patient with refractory thrombocytopenia died of an intracerebral hemorrhage after two doses of interferon. Seven of eight patients responded, with responses occurring as early as two weeks. Four patients also had resolution of their monocytopenia. No complete responses were seen with up to 30 weeks of treatment. Bone marrow biopsies demonstrated improvement in all eight patients. No unforeseen toxicity occurred, but most patients had transient myelosuppression during the first few weeks of treatment. Recombinant alpha 2 interferon is effective in the treatment of hairy cell leukemia, with acceptable toxicity.

scholarly journals Low-dose deoxycoformycin in the treatment of hairy cell leukemia

Blood ◽  
1986 ◽  
Vol 68 (5) ◽  
pp. 1119-1122 ◽  
Author(s):  
EH Kraut ◽  
BA Bouroncle ◽  
MR Grever
Keyword(s):  
Bone Marrow ◽  
Complete Remission ◽  
Hairy Cell Leukemia ◽  
Low Dose ◽  
Intravenous Bolus ◽  
Hairy Cell ◽  
Cell Leukemia ◽  
Normal Peripheral Blood ◽  
Hairy Cells ◽  
Reversible Reduction

Abstract Ten patients with progressive hairy cell leukemia were treated with 2′deoxycoformycin (dCF) by intravenous bolus (4 mg/m2) given every other week. All ten patients are evaluable for response and nine of the ten patients have achieved a complete remission. In addition to clearing of hairy cells from the bone marrow, eight patients had resolution of their monocytopenia. Seven of the nine patients remain in unmaintained remission with a median duration of 6.2 months. Two patients have had relapse in the bone marrow alone and continue to have normal peripheral blood counts. They are being followed without treatment. Toxicity was minimal at this low dose with one patient having a mild reversible reduction in creatinine clearance. Four other patients had reversible neutropenia. There were no significant infections associated with treatment. Low-dose deoxycoformycin administered intravenously every other week represents an extremely effective treatment for hairy cell leukemia.

scholarly journals Diffuse osteosclerosis in hairy cell leukemia

Blood ◽  
1989 ◽  
Vol 74 (6) ◽  
pp. 2066-2069 ◽  
Author(s):  
LA VanderMolen ◽  
WJ Urba ◽  
DL Longo ◽  
J Lawrence ◽  
H Gralnick ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Interferon Alpha ◽  
Successful Treatment ◽  
Hairy Cell Leukemia ◽  
Malignant Disease ◽  
Hairy Cell ◽  
Cell Leukemia ◽  
Bone Marrow Biopsies ◽  
Biopsy Needle ◽  
History Of

Abstract We describe two patients with a new clinical pathologic syndrome of diffuse osteosclerosis in association with hairy cell leukemia. In both patients bone marrow biopsies could not be obtained due to extremely hard bones and inability to insert the biopsy needle; neither patient had a history of bony pain or fracture. The osteosclerotic process in one patient stabilized after successful treatment of her hairy cell leukemia with interferon alpha and deoxycoformycin suggesting that the osteosclerosis observed was related to the underlying malignant disease. Possible etiologic mechanisms are discussed.

Treatment of hairy cell leukemia with alternating cycles of pentostatin and recombinant leukocyte A interferon: results of a phase II study.

1990 ◽  
Vol 8 (4) ◽  
pp. 721-730 ◽  
Author(s):  
A Martin ◽  
S Nerenstone ◽  
W J Urba ◽  
D L Longo ◽  
J B Lawrence ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Hairy Cell Leukemia ◽  
Pathologic Complete Response ◽  
Hairy Cell ◽  
Cell Leukemia ◽  
Cell Infiltrate ◽  
Recombinant Interferon ◽  
Bone Marrow Biopsies ◽  
Hairy Cells

Fifteen patients with hairy cell leukemia (HCL) were treated with deoxycoformycin (pentostatin; dCF) (4 mg/m2 intravenous [IV] every week x 3) and recombinant interferon-alpha 2a (rIFN-alpha 2a) (3 x 10(6) units subcutaneously [SC] daily x 4 weeks) in alternating months for a total of 14 months. Eleven patients had undergone splenectomy; four had received prior systemic therapy with chlorambucil and/or steroids. All 15 are evaluable for toxicity and peripheral blood response, while 14 are assessable for bone marrow response. Toxicity was tolerable with grade 3 or 4 nausea and vomiting in three patients, neutropenic fevers in five, transient but significant depression in eight, and localized cutaneous herpes zoster in four. Circulating hairy cells were undetectable by the end of the first month in 10 of 13 patients, and by the end of the second month in the other three. Fourteen patients had bilateral bone marrow biopsies performed at baseline after 6 months of treatment, at the end of treatment (14 months), and at 6-month intervals during follow-up. Before treatment, all patients had hypercellular marrows with hairy cels replacing normal marrow elements; all showed at least a 95% clearing of their hairy cell infiltrate by 6 months of therapy. However, small collections of residual hairy cells could be detected intermittently on at least one side of bilateral samples in all patients. All patients have completed treatment with a median duration of follow-up off therapy of 27 months (range, 15 to 31 months). To date, all peripheral counts and serum soluble interleukin-2 receptor (sIL2R) levels remain stable, and no patient has had progression of the hairy cell infiltrate in the bone marrow. Although no patient achieved a pathologic complete response, alternating monthly cycles of dCF and rIFN-alpha 2a produced durable partial remissions (PRs) in all patients. Continued follow-up is required to determine the length of such remissions.

scholarly journals Atypical intrasinusoidal bone marrow involvement by hairy cell leukemia

Blood ◽  
2020 ◽  
Vol 135 (5) ◽  
pp. 392-392
Author(s):  
Giovanni Martino ◽  
Stefano Ascani
Keyword(s):  
Bone Marrow ◽  
Hairy Cell Leukemia ◽  
Bone Marrow Involvement ◽  
Hairy Cell ◽  
Cell Leukemia
Sign in / Sign up

Export Citation Format

Share Document